Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Total Non-Current Liabilities (2022 - 2025)

Historic Total Non-Current Liabilities for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to $25.2 million.

  • Atara Biotherapeutics' Total Non-Current Liabilities fell 8902.85% to $25.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.2 million, marking a year-over-year decrease of 8902.85%. This contributed to the annual value of $167.4 million for FY2024, which is 2712.02% down from last year.
  • According to the latest figures from Q3 2025, Atara Biotherapeutics' Total Non-Current Liabilities is $25.2 million, which was down 8902.85% from $31.2 million recorded in Q2 2025.
  • Atara Biotherapeutics' 5-year Total Non-Current Liabilities high stood at $259.2 million for Q1 2024, and its period low was $25.2 million during Q3 2025.
  • Moreover, its 4-year median value for Total Non-Current Liabilities was $224.0 million (2024), whereas its average is $180.6 million.
  • As far as peak fluctuations go, Atara Biotherapeutics' Total Non-Current Liabilities skyrocketed by 3522.56% in 2023, and later tumbled by 8902.85% in 2025.
  • Atara Biotherapeutics' Total Non-Current Liabilities (Quarter) stood at $244.2 million in 2022, then decreased by 5.96% to $229.7 million in 2023, then decreased by 27.12% to $167.4 million in 2024, then plummeted by 84.97% to $25.2 million in 2025.
  • Its last three reported values are $25.2 million in Q3 2025, $31.2 million for Q2 2025, and $77.2 million during Q1 2025.